Consensus Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 17:57:37 15/10/2026 +04			5-day change	1st Jan Change
62.22 ^USD	+2.02%		+5.40%	+41.92%

10-09	Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says	MT
10-09	RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating	MT

Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

f0.gRNwiuxRHIIIKo5dtnyHRMHIWsyRvUB9K0g7ceyvKBA.1yNI7qYSf9tYf9Et4CnoDp77Db7mhXUvf3xJHI_qUljjIEHtvTVE6npAug~108bfe8f1ebf8e36677173fda64fea16

Analysts' recommendations: Exelixis, Inc.

10-09	Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says	MT
10-09	RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating	MT
10-08	RBC Trims Price Target on Exelixis to $45 From $46, Keeps Sector Perform Rating	MT
07-23	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07-07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
07-02	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
07-02	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
07-02	Analyst recommendations: Adobe, AA, Nike, Exelixis…
05-06	Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says	MT
03-02	RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating	MT
02-11	RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating	MT
02-02	Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating	MT
01-14	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
01-08	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
01-08	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
01-05	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
01-05	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
11-06	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
11-05	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
11-04	Exelixis Shares Fall After Guggenheim Downgrade	MT
11-03	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
21/10/25	Exelixis Shares Rise After Leerink Partners Upgrade	MT
21/10/25	Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38	MT
18/10/25	Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025	CI

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EXELIXIS, INC.					-10.04%
	WUXI APPTEC CO., LTD.					+24.45%
	ARGENX SE					+37.29%
	LONZA GROUP AG					+17.78%
	IQVIA HOLDINGS INC.					+13.35%
	REVOLUTION MEDICINES, INC.					+33.93%
	BEONE MEDICINES AG					+23.91%
	CELLTRION, INC.					+48.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+20.17%
	BIONTECH SE					+31.29%
	Average					+24.11%
	Weighted average by Cap.					+25.75%